bluebird bio Inc (BLUE) Director Sells $23,716.59 in Stock

bluebird bio Inc (NASDAQ:BLUE) Director Daniel Lynch sold 237 shares of bluebird bio stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $100.07, for a total value of $23,716.59. Following the completion of the sale, the director now owns 1,637 shares in the company, valued at $163,814.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Daniel Lynch also recently made the following trade(s):

  • On Wednesday, February 15th, Daniel Lynch sold 150 shares of bluebird bio stock. The shares were sold at an average price of $80.22, for a total value of $12,033.00.
  • On Tuesday, February 14th, Daniel Lynch sold 850 shares of bluebird bio stock. The shares were sold at an average price of $80.01, for a total value of $68,008.50.
  • On Friday, January 27th, Daniel Lynch sold 1,000 shares of bluebird bio stock. The shares were sold at an average price of $70.09, for a total value of $70,090.00.

bluebird bio Inc (NASDAQ:BLUE) traded down 0.97% during trading on Monday, hitting $91.50. The stock had a trading volume of 654,428 shares. The firm’s 50-day moving average price is $81.50 and its 200-day moving average price is $67.35. The stock’s market cap is $3.74 billion. bluebird bio Inc has a 1-year low of $35.37 and a 1-year high of $100.40.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, February 22nd. The company reported ($1.88) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.86) by $0.02. bluebird bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $1.76 million. During the same period in the prior year, the firm earned ($1.29) EPS. bluebird bio’s quarterly revenue was up 5.4% on a year-over-year basis. On average, equities research analysts predict that bluebird bio Inc will post ($7.31) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Your IP Address:

Institutional investors have recently added to or reduced their stakes in the company. Hood River Capital Management LLC bought a new position in bluebird bio during the third quarter worth approximately $8,071,000. Aperio Group LLC bought a new position in bluebird bio during the third quarter worth approximately $243,000. Berkeley Capital Partners LLC bought a new position in bluebird bio during the third quarter worth approximately $247,000. Trillium Asset Management LLC bought a new position in bluebird bio during the third quarter worth approximately $572,000. Finally, Emerald Mutual Fund Advisers Trust boosted its position in bluebird bio by 110.8% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 323,863 shares of the company’s stock worth $21,951,000 after buying an additional 170,253 shares in the last quarter.

A number of research firms recently weighed in on BLUE. Zacks Investment Research downgraded bluebird bio from a “buy” rating to a “hold” rating in a research note on Thursday, February 9th. Wedbush restated an “outperform” rating and issued a $95.00 price target on shares of bluebird bio in a research note on Thursday, December 1st. Roth Capital set a $87.00 price target on bluebird bio and gave the company a “buy” rating in a research note on Thursday, December 1st. BMO Capital Markets set a $83.00 price target on bluebird bio and gave the company a “hold” rating in a research note on Thursday, December 1st. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $95.00 price target on shares of bluebird bio in a research note on Wednesday, November 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $84.53.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for bluebird bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply